References
- Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77:1081-7
- Milsom I, Kaplan SA, Coyne KS, et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 2012;80:90-6
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
- Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
- Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
- Chapple CR, Rosenberg MT, Brenes FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009;104:960-7
- Kelleher C. New agents to treat lower urinary tract and pelvic floor disorders. Can Urol Assoc J 2013;7:S174-S6
- Wyndaele JJ, Schneider T, MacDiarmid S, et al. Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials. Int J Clin Pract 2014;68:830-40
- Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010;105:58-66
- Kaplan S, Schneider T, Foote J, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2011;107:1432-40
- Kaplan SA, Cardozo L, Herschorn S, et al. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract 2014;68:1065-73
- Sussman DO, Kraus SR, Carlsson M, Guan Z. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81
- Campbell JD, Gries KS, Watanabe JH, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol 2009;9:18
- Goldman HB, Wyndaele JJ, Kaplan SA, et al. Defining response and non-response to treatment in patients with overactive bladder: a systematic review. Curr Med Res Opin 2014;30:509-26
- Nitti VW, Kopp Z, Lin AT, et al. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourol Urodyn 2010;29:652-7
- Herschorn S, Kaplan SA, Sun F, Ntanios F. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? Urology 2014;83:1023-9
- Donovan MD. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics. J Womens Health (Larchmt) 2005;14:30-7